NCT02964585View on ClinicalTrials.gov

Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

January 31, 2020

Study Completion Date

September 30, 2020

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Canagliflozin

100 mg

DRUG

Placebo

1 tablet daily for 16 weeks

Trial Locations (1)

20037

The George Washington University Medical Faculty Associates, Washington D.C.

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

George Washington University

OTHER

NCT02964585 - Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter